A new approach to menopausal therapy: the tissue selective estrogen complex.
A new approach to menopausal therapy is the tissue selective estrogen complex or the pairing of a selective estrogen receptor modulator with estrogens. The clinical profile of a tissue selective estrogen complex will result from the blended tissue-selective activities of its components. An appropriate tissue selective estrogen complex may provide the therapeutic benefits of estrogens and selective estrogen receptor modulators with better tolerability and safety than either therapy alone. An ideal menopausal therapy would reduce the number and severity of hot flashes, effectively treat vulvar-vaginal atrophy and its symptoms, prevent and treat menopausal osteoporosis, and have favorable effects on lipoprotein profiles, while at the same time would not stimulate the endometrium, not cause uterine bleeding, not increase the risk of vascular events, not be associated with breast pain or tenderness, and potentially reduce breast cancer incidence. Here, we introduce the concept of a tissue selective estrogen complex and the rationale for its development as a next generation menopausal therapy.
Komm
Barry S
BS
Women's Health and Musculoskeletal Biology Research, Discovery Liaison, Wyeth Research, Collegeville, Pennsylvania 01242, USA. kommb@wyeth.com
D000818:Animals; D015914:Estrogen Replacement Therapy / Q000379:methods / Q000639:trends*; D004967:Estrogens / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects* / Q000378:metabolism; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000378:metabolism*; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology*; D014018:Tissue Distribution / Q000187:drug effects / Q000502:physiology
D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators